Synthesis, biological evaluation and mechanistic studies of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as a new structural class of antimicrobials

Bioorg Chem. 2023 Jul:136:106538. doi: 10.1016/j.bioorg.2023.106538. Epub 2023 Apr 13.

Abstract

In spite of several attempts to develop newer pharmacophores as potential antimicrobial agents, the benzimidazole scaffold is still considered as one of the most sought after structural component towards the design of compounds that act against a wide spectrum of microbes. Herein, we report the design and synthesis of a new structural class of 4-(1,3-thiazol-2-yl)morpholine-benzimidazole hybrids as antimicrobial agents. The most potent analog, 6g shows IC50 of 1.3 µM, 2.7 µM, 10.8 µM, 5.4 µM and 10.8 µM against Cryptococcus neoformans, Candida albicans, Candida parapsilosis, Escherichia coli and Staphylococcus aureus, respectively. Interestingly 6g exhibits selectivity towards the cryptococcal cells with fungicidal behavior. Propidium iodide uptake study shows permeabilization of pathogenic cells in the presence of 6g. Flow cytometric analysis confirms that cell death is predominantly due to apoptosis. Moreover, electron microscopic analysis specifies that it shrinks, disrupts and initiate pore(s) formation in the cell membrane leading to cell lysis.

Keywords: Benzimidazole-thiazol hybrids; Cryptococcus neoformans; Fungicidal; Membrane disruption.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents*
  • Antifungal Agents / pharmacology
  • Benzimidazoles / pharmacology
  • Candida albicans
  • Cryptococcosis*
  • Cryptococcus neoformans*
  • Humans
  • Microbial Sensitivity Tests
  • Morpholines

Substances

  • Anti-Infective Agents
  • Benzimidazoles
  • Morpholines
  • Antifungal Agents